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Abstract
Coronary reactive hyperemia (CRH) is a physiological response to ischemic insult that pre-
vents the potential harm associated with an interruption of blood supply. The relationship
between the pharmacologic inhibition of soluble epoxide hydrolase (sEH) and CRH
response to a brief ischemia is not known. sEH is involved in the main catabolic pathway of
epoxyeicosatrienoic acids (EETs), which are converted into dihydroxyeicosatrienoic acids
(DHETs). EETs protect against ischemia/reperfusion injury and have numerous beneficial
physiological effects. We hypothesized that inhibition of sEH by t-AUCB enhances CRH in
isolated mouse hearts through changing the oxylipin profiles, including an increase in
EETs/DHETs ratio. Compared to controls, t-AUCB–treated mice had increased CRH,
including repayment volume (RV), repayment duration, and repayment/debt ratio (p < 0.05).
Treatment with t-AUCB significantly changed oxylipin profiles, including an increase in
EET/DHET ratio, increase in EpOME/DiHOME ratio, increase in the levels of HODEs,
decrease in the levels of mid-chain HETEs, and decrease in prostanoids (p < 0.05). Treat-
ment with MS-PPOH (CYP epoxygenase inhibitor) reduced CRH, including RV (p < 0.05).
Involvement of PPARγ in the modulation of CRH was demonstrated using a PPARγ-antago-
nist (T0070907) and a PPARγ-agonist (rosiglitazone). T0070907 reduced CRH (p < 0.05),
whereas rosiglitazone enhanced CRH (p < 0.05) in isolated mouse hearts compared to the
non-treated. These data demonstrate that sEH inhibition enhances, whereas CYP epoxy-
genases-inhibition attenuates CRH, PPARγmediate CRH downstream of the CYP epoxy-
genases-EET pathway, and the changes in oxylipin profiles associated with sEH-inhibition
collectively contributed to the enhanced CRH.
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Introduction
Cytochrome P450 (CYP) epoxygenases catalyze the epoxidation of arachidonic acid (AA) to
form epoxyeicosatrienoic acids (EETs). Produced in endothelial cells, EETs have numerous
biological functions, including hyperpolarization and relaxation of vascular smooth muscle
cells by activating large conductance Ca2+-activated K+ channels (BKCa) [1, 2]. EETs are rap-
idly metabolized through hydration by soluble epoxide hydrolase (sEH) to the less active dihy-
droxyeicosatrienoic acids (DHETs). Although hydration by sEH is the main catabolic pathway
of EETs [3], two EET isomers, 5,6- and 8,9-EET, are substrates for the cyclooxygenase (COX)
pathway [4]. Different strategies can increase the levels of EETs to study their effects, including
transgenic models [5–7] and pharmacologic targeting of sEH [8] or CYP epoxygenases [9].
EET generation was increased in CYP2J2–over-expressed mouse cardiomyocytes and was
shown to exert cardioprotective effects against ischemia/reperfusion injury [5]. In addition to
EETs, targeting sEH impacts the levels of oxylipins (epoxyoctadecaenoic acids [EpOMEs],
dihydroxyoctadecaenoic acids [DiHOMEs], hydroxyoctadecadienoic acids [HODEs], hydro-
xyeicosatetraenoic acids [HETEs], and prostanoids) [10–13]. Lee et al. reported that sEH inhi-
bition by AUDA was associated with an increased EpOME/DiHOME ratio and improved renal
recovery against ischemia/reperfusion injury in C57BL/6 mice [14]. 13-HODE enhanced pros-
tacyclin (PGI2) biosynthesis and was involved in splenic and coronary artery relaxation in
Mongrel dogs [15]. Also, mid-chain HETEs had direct chemotactic effects on vascular tone
and on the production of endothelial vascular factors [16–19]. Further, studies indicated
that EET biological effects could be mediated by peroxisome proliferator-activated receptor-
gamma (PPARγ) [20–23]. For example, EET-induced aortic relaxation in mice was mediated
by PPARγ [7, 21].
When the heart is subjected to a brief period of ischemia, it responds by momentarily
increasing coronary blood flow [24], known as reactive hyperemia (RH) or coronary RH
(CRH). The phenomenon of CRH is associated with significant coronary vasodilation in
response to a cessation in coronary perfusion. Ischemic insult is associated with potentially det-
rimental effects on cardiac function. Increased blood flow associated with CRH prevents or
decreases injury or damage due to ischemia. By supplying an increased amount of blood to
the deprived heart muscle, CRH speeds up functional recovery and washes away accumulated
metabolic byproducts [25]. CRH is considered a protective mechanism, which is blunted or
compromised in pathologic conditions affecting the coronary circulation, including cardiac
hypertrophy [26], metabolic syndrome [27], unstable angina, myocardial infarction, and
congestive heart failure [28]. The metabolic mediators involved in RH have been studied exten-
sively, and include adenosine [26, 29, 30], nitric oxide (NO) [26], KATP channels [26] and
hydrogen peroxide (H2O2) [26, 31].
The potential effects of pharmacologic inhibition of CYP epoxygenases, inhibition of sEH,
and associated changes in oxylipin profiles on CRH in response to a short period of ischemia
have not been investigated. We hypothesized that inhibition of sEH enhances CRH through
modulation in oxylipin profiles and PPARγ, whereas inhibition of CYP epoxygenases attenu-
ates CRH in isolated mouse hearts.
Materials and Methods
Animals
The generation of sEH null (sEH–/–) mice was described by Sinal et al. [3]. sEH–/–and wildtype
(WT, sEH+/+) mice were of the C57BL/6 genetic background and provided by Dr. Darryl Zel-
din, National Institute of Environmental Health Sciences/National Institutes of Health (NIH).
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All animal care and experimentation protocols were submitted to, approved, and carried out in
accordance with the West Virginia University Institutional Animal Care and Use Committee
and were in accordance with the principles and guidelines of the NIH’s Guide for the Care and
Use of Laboratory Animals. Both male and female mice (14–16 wks old) in equal ratio were
used in our study. Mice were maintained in cages with a 12:12 h light-dark cycle and free access
to standard chow and water.
Langendorff-Perfused Heart Preparation
There are two available Langendorff technique modes to perfuse the heart: 1) constant pressure
mode and 2) constant flow mode. In our experiments, we selected the constant pressure mode.
Because the two modes have important differences, the selection between the two is particularly
important when assessing the role of coronary regulatory mechanisms in response to changing
coronary flow (CF) conditions or pathologies, such as ischemia. The constant pressure mode is
physiologically more relevant in experiments involving ischemia, like the model in our experi-
ments; therefore, it was selected over the other mode [32].
Soluble epoxide hydrolase null (sEH–/–) and wild-type (WT; sEH+/+) mice (14–16 wks.) of
both sexes (equal ratios) were euthanized with sodium pentobarbital (100 mg/kg body weight
intra-peritoneally). Hearts were excised and immediately placed into heparinized (5 U/mL)
ice-cold Krebs-Henseleit buffer containing (in mM) 119.0 NaCl, 11.0 glucose, 22.0 NaHCO3,
4.7 KCl, 1.2 KH2PO4, 1.2 MgSO4, 2.5 CaCl2, 2.0 pyruvate, and 0.5 EDTA. After removal of the
lungs and tissue surrounding the heart, the aorta was rapidly cannulated with a 20-gauge,
blunt-ended needle and continuously perfused with 37°C buffer continuously bubbled with
[95% O2]–[5% CO2] at a constant perfusion pressure of 80 mmHg. The left atrium was excised,
and a water-filled balloon made of plastic wrap was inserted into the left ventricle through
the mitral valve. The balloon was connected to a pressure transducer for continuous measure-
ment of left ventricular developed pressure (LVDP) and heart rate (HR). The heart was then
immersed in a water-jacketed perfusate bath (37°C) and left to beat spontaneously. Left ven-
tricular diastolic pressure was adjusted to 2–5 mmHg. A flow transducer was installed above
the cannulated aorta for continuous measurement of CF with an ultrasonic flow probe (Tran-
sonic Systems, Ithaca, NY). A Power–Lab Chart data acquisition system (AD Instruments, Col-
orado Springs, CO) was used for data acquisition. Heart function was allowed to stabilize for
30–40 min before initiation of CRH. Only hearts whose CF increased by more than two fold
after a 15-second total occlusion were included in the analysis. This demonstrated that the iso-
lated heart preparation was intact to be included in the experiment. Hearts with persistent
arrhythmias or LVDP<80 mmHg were excluded.
Coronary Reactive Hyperemic Response
After stabilization for 30–40 minutes, baseline CF, HR, and LVDP were recorded. Hearts were
subjected to 15 seconds of total occlusion by closing the valve directly above the cannulated
heart to bring forth CRH. After CF returned to pre-CRH baseline levels, post-CRH baseline
CF, CF tracing, peak hyperemic flow (PHF), HR, LVDP, repayment volume (RV), and repay-
ment duration (RD) recordings were analyzed for each isolated heart. Investigational drugs
were infused into the aortic perfusion line using a microinjection pump (Harvard Apparatus,
Holliston, MA) for 15 minutes, after which another CRH was induced and the same parame-
ters analyzed again. Drugs were infused at a rate equivalent to 1% of CF. The final concentra-
tions, after standardization of dose (0.01, 0.1, 1, & 10 μM) response for the various drugs used
in this study were 10 μM for T0070907 (PPARγ-antagonist), rosiglitazone (PPARγ-agonist), t-
AUCB (trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid (a selective sEH-
Soluble Epoxide Hydrolase and Coronary Reactive Hyperemia
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inhibitor, University of California, Davis), and 1 μM for MS-PPOH (methylsulfonyl-propargy-
loxyphenylhexanamide, CYP-epoxygenases inhibitor). These concentrations are the same, or
less, as used in previous studies: rosiglitazone, 10 μM; [33], t-AUCB, 10 μM; [34], MS-PPOH,
1 μM [35].
Effect of t-AUCB on CRH Response
After stabilization for 30–40 min, isolated WT mouse hearts were subjected to 15 sec of total
occlusion. Recordings of the first CRH (baseline CF, CF tracing, LVDP, HR, RV, PHF, and
RD) were analyzed for each heart and averaged. t-AUCB was infused at a final concentration
of 10 μM and 1% of CF rate for 15 min, after which another CRH was induced and the same
parameters (baseline CF, CF tracing, LVDP, HR, RV, and RD) were recorded again and
analyzed.
Effect of t-AUCB on CRH Response in sEH–/–Mice:
To investigate the specificity of the sEH-inhibitor, t-AUCB, we evaluated its effect on CRH in
sEH–/–mouse hearts, where the sEH gene is globally deleted. We followed the same protocol
described above. CRH was induced in sEH–/–mice before and after infusing t-AUCB for 15
min. The two CRH responses were analyzed.
LC–MS/MS Oxylipin Analysis
Levels of oxylipins (5,6-, 8,9-, 11,12- and 14,15-EET, 5,6-, 8,9-, 11,12- and 14,15-DHET, 5-, 8-,
9-, 11-, 12- and 15-HETE, 9,10- and 12,13-EpOME, 9,10- and 12,13-DiHOME, 9- and
13-HODE, 6-keto prostaglandin-F1α [6K-PG-F1α], PG-F2α, thromboxane B2 [TxB2], PGD2,
and PGE2) were determined in pre- and post-CRH heart perfusates of WT and t-AUCB-
treated WTmice through liquid chromatography, tandem mass spectroscopy (LC-MS/MS) as
described previously [36]. Heart perfusates were collected after the first 30 min of stabilization
and right after reperfusion for 2.5 min. Hearts were immersed in 5 mL of warm (37°C) Krebs-
Henseleit buffer with 5 μL of 10 μM t-AUCB to block further EET breakdown by sEH. Heart
perfusates were collected two times before ischemia (baseline) and pooled together as one sam-
ple and two times after ischemia and pooled together as another sample for LC-MS/MS analy-
sis. Samples were stored at –80°C until processing. Samples were spiked with 30 ng PGE2-d4,
10,11- DiHN, and 10,11-EpHep (Cayman) as internal standards, mixed with 0.1 vol of 1% ace-
tic acid in 50% methanol, and extracted by serial passage through Oasis HLB C18 3mL col-
umns (Waters, Milford, MA, USA). Columns were washed twice with 0.1% acetic acid in 5%
methanol and eluted with methanol into glass tubes containing 6 μL of 30% glycerol in metha-
nol. The methanol was then evaporated under a stream of nitrogen gas, and the dried tubes
were frozen and stored at –80°C until analysis. Online liquid chromatography of extracted
samples was performed with an Agilent 1200 Series capillary HPLC (Agilent Technologies,
Santa Clara, CA, USA). Separations were achieved using a Halo C18 column (2.7 mm, 10062.1
mm; MAC-MOD Analytical, Chadds Ford, PA), which was held at 50°C. Mobile phase A was
85:15:0.1 water: acetonitrile: acetic acid. Mobile phase B was 70:30:0.1 acetonitrile: methanol:
acetic acid. Flow rate was 400 μL/min; Gradient elution was used. Mobile phase percentage B
and flow rate were varied as follows: 20% B at 0 min, ramp from 0 to 5 min to 40% B, ramp
from 5 to 7 min to 55% B, ramp from 7 to 13 min to 64% B. From 13 to 19 min the column
was flushed with 100% B at a flow rate of 550 μL/min. Samples were solvated in 50 μl of 30%
ethanol. The injection volume was 10 μL. Samples were analyzed in triplicate. Analyses were
performed on an MDS Sciex API 3000 equipped with a TurboIonSpray source (Applied Bio-
systems). Turbo desolvation gas was heated to 425°C at a flow rate of 6 L/min. Negative ion
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electrospray ionization tandem mass spectrometry with multiple reaction monitoring was used
for detection.
Effect of MS-PPOH (CYP epoxygenase inhibitor) on CRH Response
Isolated WT mice hearts were stabilized for 30–40 min, followed by 15 sec of total occlusion.
Recordings of the first CRH (baseline CF, CF tracing, LVDP, HR, RV, PHF and RD) were ana-
lyzed for each heart and averaged. MS-PPOH was infused at a final concentration of 1.0 μM
for 15 minutes, after which the second CRH was induced. CRHs before and after MS-PPOH
infusion were analyzed and compared.
Effect of T0070907 (PPARγ antagonist) on CRH Response
Isolated WT mouse hearts were stabilized for 30–40 min followed by 15 sec of total occlusion.
Recordings of the first CRH (baseline CF, CF tracing, LVDP, HR, RV, PHF and RD) were ana-
lyzed for each heart and averaged for each group, as mentioned previously. T0070907 was
infused at a final concentration of 10 μM and 1% of CF rate for 15 min, after which another
CRH was induced and the same parameters (baseline CF, CF tracing, LVDP, HR, RV, and RD)
were recorded again and analyzed.
Effect of t-AUCB and T0070907 on CRH Response
In this experiment, we investigated a possible link between the role of PPARγ in CRH and
pharmacological inhibition of sEH by t-AUCB. We evaluated the effects of selective sEH-inhi-
bition on CRH followed by PPARγ-antagonist. Baseline CRH was induced in WT mice. t-
AUCB was infused at a final concentration of 10 μM for 15 minutes, after which a second CRH
was induced. T0070907 was infused while t-AUCB was still being infused, at a final concentra-
tion of 10 μM for another 15 min, and a third CRH was induced. The three CRH responses
were analyzed and compared.
Effect of Rosiglitazone on CRH Response
After stabilization, WT mouse hearts were subjected to 15 sec of total occlusion. As described
above, baseline CRH was induced in each mouse heart. Rosiglitazone was infused at a final con-
centration of 10 μM for 15 min, followed by another CRH. CRHs before and after rosiglitazone
infusion were analyzed and compared.
Statistical and Data Analyses
Flow debt (baseline flow rate multiplied by occlusion duration) and RV (the integral of hyper-
emic area above the baseline flow) were calculated using “the integral relative to baseline” func-
tion in the data pad of Lab-Chart 7.0 software. Since absolute coronary flow rates change
proportionally with heart mass, the RV and flow debt are presented as ml/g wet heart weight,
and baseline and peak flow rate data are presented as (mL.min–1.g wet heart weight–1). Values
are means ± standard error; n represents the number of animals. For data analysis, two-tailed
paired t-tests were used for paired data analysis, repeated measures ANOVAs were used for
populations measured 3 times, and two-way ANOVAs were used to compare data between
groups. Differences were considered statistically significant when p< 0.05.
Soluble Epoxide Hydrolase and Coronary Reactive Hyperemia
PLOS ONE | DOI:10.1371/journal.pone.0162147 September 1, 2016 5 / 22
Results
CRH Response
Effect of t-AUCB on CRH Response in WTMice. t-AUCB enhanced CRH inWTmice
(Fig 1A). Compared to WT mice, t-AUCB-treated WT mice had increased RV (41%; 6.1 ± 0.5
and 8.5 ± 0.4 mL/g, respectively; p< 0.05, Fig 1B), increased RD (64%; 1.6 ± 0.2 and 2.7 ± 0.4,
respectively; Fig 1C), an increased repayment/debt (R/D) ratio (36%; 1.5 ± 0.1 and 2.1 ± 0.2,
respectively; p< 0.05; Fig 1D), and slightly increased PHF (39.7 ± 0.7 and 41.2 ± 1.0 mL/min/g
respectively, p< 0.05; Fig 1E). Baseline CF, LVPD, and HR were not different between the two
groups (p> 0.05). Time-matched control experiments with WT mouse hearts, employing
three consecutive inductions of CRH, showed no change in the CRH response and no differ-
ence in baseline heart functions, including CF, LVDP, and HR (data not shown).
Effect of t-AUCB on CRH Response in sEH–/–Mice
Using the same experimental protocol as in the preceding section, t-AUCB did not have a sig-
nificant effect on CRH in sEH–/–mice, including RV (p> 0.05, Fig 2A), R/D (p> 0.05, Fig 2B),
RD (p> 0.05, Fig 2C), baseline CF, PHF, HR, or LVDP (data not shown).
Oxylipin Analysis of Heart Perfusate before and after t-AUCB infusion in
WTMice
Heart perfusate oxylipin levels were determined by LC–MS/MS. Perfusate samples were col-
lected at baseline after stabilization and right after ischemia in WT and t-AUCB-treated WT
Fig 1. Comparison of coronary reactive hyperemia (CRH) before (WT) and after (t-AUCB-treatedWT) infusion of t-
AUCB. (A) tracing depicting coronary flow (CF) changes at baseline (before CRH) and after CRH was induced by
15-second no-flow ischemia in WT (continuous line) andWT + t-AUCB (dashed line). Repayment volume (B), repayment
duration (C), repayment/debt ratio (D), and peak hyperemic flow (E) increased in t-AUCB-treated WT versusWTmice
(p < 0.05). * p < 0.05 versusWT. n = 8.
doi:10.1371/journal.pone.0162147.g001
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mice. Out of the four EET regioisomers, only 14,15-EET, its corresponding metabolite
(14,15-DHET), and 11,12-DHET were detected. An increasing trend in the level of 14,15-EET
in t-AUCB-treated WT versus WT mice was observed at baseline and post-ischemia, but was
not significant (p> 0.05, Fig 3A). However, sEH-metabolized 14,15-DHET significantly
decreased in t-AUCB-treated WT versus WT mice at baseline and post-ischemia (p< 0.0001,
Fig 3B). As a result, the ratio of 14,15-EET/DHET increased in t-AUCB-treated WT versus
WT mice at baseline (by 96%) and post-ischemia (by 173%; p< 0.05, Fig 3C). Our technique
also detected 11,12-DHET, which decreased in t-AUCB-treated WT versus WTmice at base-
line and post-ischemia (p< 0.001, Fig 3D). There was no differences in levels of 14,15-EET,
14,15-DHET, or 11,12-DHET pre- and post-ischemia within each group.
Our LC–MS/MS detected 4 mid-chain HETEs (5-, 11-, 12-, and 15-HETE) in WT and t-
AUCB-treated WT mouse heart perfusates. In WT mice, levels of 5-, 11-, 12-, and 15-HETE
decreased post-ischemia (after perfusion was reinstated) compared to baseline, but this was
only significant for 5-, 11-, and 15-HETE (p< 0.05, Fig 4A, 4B and 4D). These mid-chain
HETEs had a decreasing trend post-ischemia compared to baseline in t-AUCB-treated WT
mice, but this trend was not significant (p> 0.05, Fig 4A–4D). Treatment with t-AUCB
decreased HETE levels in WT mice, which was significant for 5-, 11-, and 15-HETE at baseline
(p< 0.05, Fig 4A, 4B and 4D) and 11-HETE post-ischemia (p< 0.05, Fig 4B).
Linoleic acid (LA) epoxides (9,10- and 12,13-EpOME) levels had an increasing trend at
baseline and post-ischemia in t-AUCB-treated WT versus WT mice, but was not significant
(p> 0.05, Fig 5A). The corresponding 9, 10- and 12, 13-DiHOME levels decreased at baseline
and post-ischemia in t-AUCB-treated WT versus WT mice (p< 0.001, Fig 5B). As a result, the
EpOME/DiHOME ratio increased in t-AUCB-treated WT compared to WTmice at baseline
and post-ischemia (p< 0.0001, Fig 5C). The measured EpOMEs, DiHOMEs, and EpOME/
DiHOME ratio did not change post-ischemia versus baseline within the same group (p> 0.05,
Fig 5A–5C).
Other LA hydroxylated metabolites, 9- and 13-HODE, increased in t-AUCB-treated WT
versus WT mice at baseline and post-ischemia (p< 0.05, Fig 6); however, neither HODE level
changed post-ischemia versus baseline within the same group (p> 0.05, Fig 6).
The levels of 6K-PG-F1α, PG-F2α, TxB2, PG-D2, and PG-E2 was also detected by our LC–
MS/MS. Treatment of WT mouse hearts with t-AUCB at baseline and post-ischemia decreased
6-keto-PG-F1α (p< 0.05, Fig 7A), PG-F2α (p< 0.05, Fig 7B), TxB2 (p< 0.05, Fig 7C), PG-D2
(p< 0.05, Fig 7D), and PG-E2 (p< 0.05, Fig 7E). Compared to baseline WT levels, post-
Fig 2. Effect of sEH-inhibitor, t-AUCB, on coronary reactive hyperemia (CRH) in sEH-null (sEH–/–) mice. t-AUCB did
not (p > 0.05) affect CRH in sEH–/–mice, as evident in the unchanged repayment volume (A), repayment/debt ratio (B),
and repayment duration (C) (p = 0.690). n = 6.
doi:10.1371/journal.pone.0162147.g002
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ischemia WT levels decreased for TxB2 and PG-D2, but were significant (p< 0.05) only for
TxB2 (Fig 7C).
Effect of MS-PPOH (CYP epoxygenase inhibitor) on CRH Response in
WTMice
MS-PPOH attenuated CRH in WT mice (Fig 8A). RV was decreased by 19% in MS-PPOH-
treated WT versus WT mice (6.6 ± 0.4 and 5.3 ± 0.4 mL/g respectively, p < 0.05, Fig 8B).
Fig 3. LC–MS/MS analysis for 14, 15–EET, 14, 15–DHET, and 11,12–DHET levels in WT and t-AUCB-treatedWT
mouse heart perfusates at baseline (pre-ischemia) and directly after 15-second ischemia (post-ischemia). (A) At
baseline and post-ischemia levels of 14, 15–EET had an increasing trend in t-AUCB-treatedWT versusWTmice, but this
trend was not significant. (B) 14, 15–DHET levels decreased at baseline and post-ischemia in t-AUCB-treated WT versus
WT (p < 0.0001). (C) The 14, 15–EET/14, 15–DHET ratio increased (p < 0.05) in t-AUCB-treatedWT versusWTmice at
baseline (by 96%) and post-ischemia (by 173%). (D) 11, 12–DHET levels decreased (p < 0.001) at baseline and post-
ischemia in t-AUCB-treated-WT versusWTmice. There was no difference in 14,15-EET, 14,15-DHET, and 11,12-DHET
levels pre- and post-ischemia within each group. * p < 0.05 versus baselineWT. # p < 0.05 versus post-ischemiaWT.
n = 8.
doi:10.1371/journal.pone.0162147.g003
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Baseline CF was also decreased by 26% in MS-PPOH-treated WT versus WT mice
(13.2 ± 0.4 and 9.7 ± 0.6 mL/g respectively, p < 0.05, Fig 8E). As a result, the debt volume
(calculated as the area under the CF curve during the 15 second ischemia) was decreased
and, subsequently, the R/D ratio was increased in MS-PPOH-treated WT compared to WT
mice (1.9 ± 0.1 and 2.4 ± 0.2 respectively, p < 0.05, Fig 8C). PHF was slightly decreased in
MS-PPOH-treated WT versus WT mice (33.6 ± 0.7 and 32.4 ± 0.7 mL/min/g respectively,
p< 0.05, Fig 1F). RD (Fig 8D), HR, and LVPD were not different between the two groups
(p > 0.05).
Fig 4. LC–MS/MS analysis of 5-, 11-, 12- and 15-HETE levels in WT and t-AUCB-treatedWTmouse heart
perfusates at baseline (pre-ischemia) and post-ischemia. In WTmice, 5-, 11-, 12- and 15-HETE levels decreased
post-ischemia compared to baseline, but this was only significant for 5-HETE (A), 11-HETE (B), and 15-HETE (D)
(p < 0.05). The samemid-chain HETEs had a decreasing trend post-ischemia compared to baseline in t-AUCB-treated
WTmice, but this was not significant (p > 0.05, A-D). Treatment with t-AUCB decreased HETE levels in WTmice, which
was significant for 5-HETE (A), 11-HETE (B) and 15-HETE (D) levels at baseline (p < 0.05), and in 11-HETE levels post-
ischemia (p < 0.05, B). * p < 0.05 versus baselineWT. # p < 0.05 versus post-ischemia WT. n = 8.
doi:10.1371/journal.pone.0162147.g004
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Effect of T0070907 (PPARγ antagonist) on CRH response in WTMice
Administering T0070907 to WTmouse hearts attenuated CRH. In T0070907-treated WT ver-
sus WT mice, RV was decreased by 32% (from 6.6 ± 0.7 to 4.5 ± 0.6 mL/g, p< 0.05, Fig 9A),
RD by 50% (from 2.1 ± 0.5 to 1.1 ± 0.2 min, p< 0.05, Fig 9B), and baseline CF by 10% (from
16.3 ± 0.7 to 15.1 ± 1.5 mL/min/g, p< 0.05, Fig 9D). The R/D ratio decreased from 1.7 ± 0.3 to
1.2 ± 0.1, but was not significant (p> 0.05, Fig 9C). LVDP, PHF, and HR were not different
between the two groups (p> 0.05, data not shown).
Effect of T0070907on t-AUCB–enhanced CRH in WTMice
Pharmacologic inhibition of sEH by t-AUCB enhanced CRH inWTmice, as mentioned earlier
(Fig 1). This same experiment was repeated with the PPARγ-antagonist T0070907 added to
study its effect on t-AUCB-enhanced CRH. Infusion of t-AUCB increased RV in WTmice
(from 6.0 ± 0.7 to 7.6 ± 0.5 mL/g, p< 0.05, Fig 10A), R/D ratio (from 1.4 ± 0.1 to 1.9 ± 0.2,
p< 0.05, Fig 10B), and RD (from 1.6 ± 0.2 to 3.1 ± 0.3, p< 0.05, Fig 10C). t-AUCB–enhanced
CRH was attenuated by T0070907. Addition of T0090709 to t-AUCB-treated WTmice
Fig 5. LC–MS/MS analysis of EpOME and DiHOME levels and the EpOME/DiHOME ratio in WT and t-AUCB-
treated-WTmouse heart perfusates at baseline (pre-ischemia) and post-ischemia. (A) 9,10- and 12,13-EpOME
levels had an increasing trend at baseline and post-ischemia in t-AUCB-treated-WT versusWTmice, but this was not
significant (p > 0.05). Neither EpOMEwas significantly changed post-ischemia compared to baseline in both groups. (B)
9,10- and 12,13-DiHOME levels decreased at baseline and post-ischemia in t-AUCB-treated-WT versusWTmice
(p < 0.001). (C) The EpOME/DiHOME ratio increased in t-AUCB-treated versusWTmice at baseline and post-ischemia
(p < 0.0001). The measured EpOME and DiHOME levels and EpOME/DiHOME ratio did not change post ischemia versus
baseline within the same group (p > 0.05, A-C). * p < 0.05 versus baselineWT. # p < 0.05 versus post-ischemiaWT. n = 8.
doi:10.1371/journal.pone.0162147.g005
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Fig 6. LC–MS/MS analysis of HODEs inWT and t-AUCB-treatedWTmouse heart perfusates at
baseline (pre-ischemia) and post-ischemia. 9- and 13-HODE increased in t-AUCB-treatedWT versusWT
mice at baseline and post-ischemia (p < 0.05). Neither HODE changed post-ischemia versus baseline within
the same group (p > 0.05). * p < 0.05 versus baselineWT. # p < 0.05 versus post-ischemia WT. n = 8.
doi:10.1371/journal.pone.0162147.g006
Fig 7. LC–MS/MS analysis of 6-keto-PG-F1α, PG-F2α, thromboxane B2, PG-D2, and PG-E2 in WT and t-AUCB-
treatedWTmouse heart perfusates at baseline (pre-ischemia) and post-ischemia. Infusion of t-AUCB decreased
6-keto-PG-F1α (A), PG-F2α, (B), thromboxane B2 (C), PG-D2 (D), and PG-E2 (E), at baseline and post-ischemia (p < 0.05).
Compared to baselineWT, post-ischemiaWT levels were decreased for thromboxane B2, and PG-D2, but were significant
(p < 0.05) only for thromboxane B2 (C). * p < 0.05 versus baselineWT. # p < 0.05 versus post-ischemia WT. n = 8.
doi:10.1371/journal.pone.0162147.g007
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decreased RV (from 7.6 ± 0.5 to 4.3 ± 0.2 mL/g, p< 0.05, Fig 10A), R/D ratio (from 1.9 ± 0.2 to
1.1 ± 0.2, p< 0.05, Fig 10B) and RD (from 3.1 ± 0.3 to 1.6 ± 0.3, p> 0.05, Fig 10C). Baseline
CF, PHF, HR and LVDP were not significantly changed among the 3 groups (WT, [WT + t-
AUCB], and [WT + t-AUCB + T0070907], data not shown).
Effect of rosiglitazone (PPARγ agonist) on CRH Response in WT Mice
Infusion of rosiglitazone enhanced CRH inWT mice. In rosiglitazone-treated WT versus WT
mice, RV increased by 33% (from 6.1 ± 0.3 to 8.1 ± 0.9 mL/g, p< 0.05, Fig 11A), RD by 33%
(from 1.6 ± 0.1 to 2.1 ± 0.3 min, p< 0.05, Fig 11B), R/D ratio by 31% (from 1.6 ± 0.1 to
1.9 ± 0.2, p< 0.05, Fig 11C), and baseline CF from 15.2 ± 0.1 to 17.1 ± 0.7 mL/min/g
(p< 0.05, Fig 11D). PHF, LVDP and HR were not different between the two groups (p> 0.05,
data not shown). We summarized our observed results into a proposed schematic diagram
(Fig 12).
Discussion
Pharmacologic inhibition of sEH in WT mice enhanced CRH in an isolated heart model after
brief ischemia. sEH inhibition was also associated with changes in various oxylipin profiles.
The relationship among inhibition of CYP epoxygenases, inhibition of sEH, oxylipins, and
PPARγ in the modulation of CRH in isolated mouse hearts is not known. Therefore, this study
was designed to investigate the role of sEH, oxylipins, and PPARγ in the modulation of CRH
using isolated WTmouse hearts. Our data demonstrated that: 1) Inhibition of sEH by t-AUCB
enhanced CRH; 2) Treatment with t-AUCB significantly changed oxylipin profiles, including
Fig 8. Effect of CYP-epoxygenase inhibitor (MS-PPOH, 1 μM) on coronary reactive hyperemia (CRH) in wild type
(WT) mice. EachWT isolated mouse heart was used as its own control. (A) tracing depicting coronary flow changes at
baseline (before CRH) and after CRH was induced by 15-second no-flow ischemia in WT (continuous line) and
MS-PPOH-treatedWT (dashed line) mice. Repayment volume (B), baseline CF (E), PHF (F), and LVDP (G) decreased
(p < 0.05) in MS-PPOH-treatedWT versusWTmice. Repayment/debt ratio (C) increased (p < 0.05), whereas repayment
duration (D) did not change (p > 0.05) after in MS-PPOH-treatedWT versusWTmice. * p < 0.05 versusWT. n = 8.
doi:10.1371/journal.pone.0162147.g008
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Fig 9. Effect of T0070907, PPARγ-antagonist (10 μM) on coronary reactive hyperemia (CRH) in wild type (WT)
mice. EachWT isolated mouse heart was used as its own control. Infusion of T0070907 into WTmice hearts attenuated
CRH. (A) Repayment volume decreased (p < 0.05), as did RD (B) (p < 0.05) and baseline CF (D) (p < 0.05). Repayment/
debt ratio (C) had a decreasing trend, but was not significant (p > 0.05). * p < 0.05 versusWT. n = 8.
doi:10.1371/journal.pone.0162147.g009
Fig 10. Effect of T0070907, PPARγ-antagonist (10 μM) on t-AUCB-enhanced CRH inWT in wild type (WT) mice.
EachWT isolated mouse heart was used as its own control. Inhibition of sEH by t-AUCB enhanced CRH inWTmice.
Infusion of t-AUCB (10 μM) increased repayment volume (RV) (p < 0.05, A), repayment/debt ratio (p < 0.05, B), and
repayment duration (RD) in WTmice (p < 0.05, C). The t-AUCB-enhanced CRH was attenuated by T0070907. T0070907
decreased RV (A), R/D ratio (B), and RD (C) in t-AUCB-treated-WTmice (p < 0.05). * p < 0.05 versusWT. n = 6.
doi:10.1371/journal.pone.0162147.g010
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an increased EET/DHET ratio, increased EpOME/DiHOME ratio, increased HODEs,
decreased mid-chain HETEs, and decreased prostanoids; 3) Inhibition of CYP epoxygenases
(by MS-PPOH) attenuated CRH; 4) The PPARγ antagonist T0070907 decreased CRH, and 5)
the PPARγ agonist rosiglitazone increased CRH.
Inhibition of sEH by t-AUCB significantly enhanced CRH after brief ischemia compared to
non-treated WTmice. The association between compromised CRH and some cardiovascular
pathologies [26–28] confirms the significance of CRH. Further, the t-AUCB-enhanced CRH
was accompanied by a 1.0- (at baseline) to 1.7- (post-ischemia) fold increase in the 14,15-EET/
DHET ratio, primarily driven by a decrease in 14,15-DHET. Although, a trend of increase in
14,15-EET level was observed in t-AUCB–treated vs. non-treated WTmice, the difference was
not statistically significant. This could be attributed to several factors including the acute use of
t-AUCB for a short period, the short half-life of EETs compared to DHETs, and the short dura-
tion (15 seconds) of ischemic insult. Another dihydroxy-EET metabolite (11,12-DHET)
decreased in t-AUCB–treated mouse hearts, further confirming the efficacy of the sEH-inhibi-
tor, t-AUCB. The specificity of t-AUCB as a sEH inhibitor was tested using sEH knockout
(sEH–/–) mice, where no difference in CRH between the t-AUCB-treated sEH–/–versus non-
treated sEH–/–mice was observed. The rapid hydration of EETs [37] may explain the challenge
of detecting them. We were able to detect 14,15-EET and two diols (11,12- and 14,15-DHETs)
in heart perfusate samples. As mentioned earlier, EETs are formed by the epoxidation of
Fig 11. Comparison of CRH inWT before and after infusion of rosiglitazone (PPARγ-agonist, 10 μM). Each isolated
heart was used as its own control. Repayment volume (A), repayment duration (B), repayment/debt ratio (C), and baseline
CF (D) increased after rosiglitazone administration (p < 0.05). * p < 0.05 versusWT. n = 8.
doi:10.1371/journal.pone.0162147.g011
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arachidonic acid (AA) by CYP epoxygenases and possess well-established beneficial cardiovas-
cular effects [7, 38–41], including protection against ischemia/reperfusion injury [5], and vaso-
dilation in many vascular beds such as the intestines [42], kidney preglomerular vasculature
[43], and brain [44]. Inhibition of sEH, the main catabolic enzyme of EETs, has been widely
used to increase the level of EETs and to investigate their effects [11]. Acute inhibition of sEH,
through injection of a sEH inhibitor, lowered blood pressure in spontaneously hypertensive
rats (SHR) [45], whereas chronic inhibition of sEH lowered angiotensin-II–induced hyperten-
sion [46]. Besides lowering blood pressure, sEH inhibition ameliorated renal damage in angio-
tensin-dependent, salt-sensitive hypertension rats [47]. In the current study, the brief ischemia
had no effect on EET or DHET levels. This could be due to the short duration of ischemia (15
seconds). In contrast, DHETs (EETs metabolites) were elevated in the mouse heart perfusate in
response to longer (20-min) ischemia [6]. Another interesting finding in the current study was
that no significant difference was found in CRH between male and female mice in either t-
AUCB–treated or non–treated groups (data not presented). Based on our data, the enhance-
ment of CRH associated with sEH inhibition in WTmice may be partially due to an increase in
the EET/DHET ratio.
Mid-chain (5-, 11-, 12- and 15-) HETE levels decreased in response to ischemia and to t-
AUCB treatment at baseline and post-ischemia. Mid-chain HETEs are produced through
allylic oxidation of AA by lipoxygenase (LOX) [48]. They were shown to have chemotaxis
effects, change vascular tone, and induce the production of vascular endothelial growth factors
[16–19]. Also, the increased formation of mid-chain HETEs was involved in cardiovascular
dysfunction [49–52]. Unlike the vasodilatory effect of EETs in the kidneys [43], 12-HETE
caused vasoconstriction in small renal arteries [53]. In human umbilical artery smooth muscle
cells, 11-HETE inhibited vascular smooth muscle cell proliferation [54], whereas in the isolated
Guinea Pig lungs, 5- and 15-HETEs produced vasoconstriction and edema [55]. Also, the gen-
eration of mid-chain HETEs is increased in essential hypertension [56] suggesting that they
could be involved in its pathogenesis. These reports point to opposite effects of EETs and
HETEs in vascular biology. Maayah et al. reported that mid-chain HETEs blocked the synthesis
Fig 12. A schematic diagram comparing the oxylipin changes observed in response to a brief
ischemia and their possible impact on coronary reactive hyperemia (CRH) betweenWT and t-AUCB-
treatedWTmice. Treatment with t-AUCB enhanced CRH possibly through increased EET/DHET ratio,
increased 13-HODE, increased EpOME/DiHOME ratio, decreased mid-chain HETEs, and PPARγ activation.
doi:10.1371/journal.pone.0162147.g012
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of EETs and increased their conversion to DHETs in RL-14 cells [57]. Moreover, although sEH
is not directly involved in the generation or breakdown of mid-chain HETEs, sEH was found
to be essential for mid-chain HETE–mediated induction of cellular hypertrophy [57]. There-
fore, not only do EETs and mid-chain HETEs have opposite effects, they seem to affect the
level of each other. In contrast to our findings, Li et al. reported that the plasma levels of 5-, 11-
, 12-, and 15-HETE were not changed by sEH-inhibition in WTmice [11]. However, their
results were based on plasma samples, whereas ours were based on isolated heart perfusate
samples and demonstrated significant decrease in the level of the same HETEs in response to
sEH inhibition. Therefore, in this study, it is possible that the decrease in mid-chain HETEs
induced by sEHi (t-AUCB) has also contributed to blocking the enhanced conversion of EETs
to DHETS by HETEs. This in turn would contribute to the enhanced CRH through an increase
in EET/DHET ratio. Based on these results, the decrease in mid-chain HETEs in both t-
AUCB-treated and non-treated mice in response to ischemia suggests that these metabolites
are down regulated in response to ischemic episodes. This is an interesting finding because
HETEs were the only oxylipins analyzed in this paper whose levels were affected by the brief
ischemia. Also, the further decrease of these HETEs by t-AUCB–treatment may have played a
role in the enhanced CRH observed in t-AUCB–treated hearts.
Linoleic acid (LA) epoxidation metabolites, such as 9,10-, and 12,13-EpOMEs, and their
corresponding sEH-metabolized DiHOMEs were detected in the heart perfusate samples. As
expected, inhibition of sEH by t-AUCB was further confirmed by an increased EpOME/
DiHOME ratio. This resulted from increased 9,10-,12,13-EpOMEs (albeit not statistically sig-
nificant), and decreased 9,10-, 12,13-DiHOMEs in t-AUCB–treated versus non-treated mice.
The physiological significance of EpOMEs and DiHOMEs remains poorly understood, and the
evidence is somewhat contradictory, with a few studies suggesting toxic effects, while others
indicating beneficial effects of these bioactive metabolites. EpOMEs and DiHOMEs were
reported to increase oxidative stress in vascular endothelial cells [58]; DiHOMEs were toxic to
renal proximal tubular cells [59]; and intravenously injected 9,10-EpOME had cardiodepres-
sive effects in dogs [60]. The main caveat of these studies, which reported that EpOMEs and
DiHOMEs have toxic effects, is that very high concentrations (100–500 μM) were used [48].
Contrary to these reports, lower, more physiological concentrations of EpOMEs and
DiHOMEs did not have toxic effects and rather had beneficial effects [61]. Mitchell et al
reported that LA and its oxidative metabolites (EpOMEs and DiHOMEs) did not have toxic
effects during acute exposure in Langendorff-perfused rat hearts [61]. Pretreatment with
12,13-EpOME protected primary cultures of rabbit renal proximal tubular cells against hyp-
oxia/reoxygenation injury [62]. Also, the increased EpOME/DiHOME ratio, as induced by
sEH inhibition using AUDA, improved renal recovery in response to ischemia/reperfusion
injury in C57BL/6 mice [14]. Based on these findings and on the described biologic role of LA
epoxides, the increase in EpOME/DiHOME ratio in t-AUCB–treated mouse heart perfusates
may have contributed to enhancing CRH.
Linoleic acid (LA) is also metabolized through hydroxylation by CYP epoxygenases to form
hydroxyl-LA metabolites known as hydroxyoctadecadienoic acids (HODEs) [48]. The detected
two HODE isomers, 9-, and 13-HODE, were increased in t-AUCB-treated WT. Like EpOMEs,
the physiologic functions of HODEs are still being investigated [48]. 13-HODE is suggested to
have an anti-inflammatory role in inflammatory diseases through its effect as a PPARγ-agonist
[63–67]. Also, 13-HODE, through increasing prostacyclin (PGI2) biosynthesis, was involved in
splenic and coronary artery relaxation in smooth muscle cells in Mongrel dogs [15]. 9-HODE,
unlike 13-HODE, was described as pro-inflammatory in an experimental wound-healing
model in rats [68, 69]. In contrast to 13-HODE, which can be produced from LA by the action
of 12/15-LOX, 9-HODE production by LOX has not been reported in humans; rather, mouse
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8-LOX metabolizes LA to 9-HODE [68]. In contrast to our data, Luria et al. reported no change
in 9– and 13–HODE in sEH–/–compared to sEH+/+ [10]. This discrepancy may be explained by
the difference in the source of the metabolites: we used heart perfusate samples, whereas Luria
et al [10] used urinary samples. Also, the reported metabolic and functional effects of sEH–/
–(genetic deletion of sEH) and pharmacologic inhibition of sEH are not necessarily the same
[11]. Therefore, and based on our results, the increase in 13-HODE in t-AUCB–treated mouse
heart perfusates might have played a role in enhancing CRH, whereas the role of 9-HODE is
not yet known based on its, thus far, described biologic functions.
Treatment of WT mice hearts with t-AUCB significantly decreased prostanoid levels,
including PGs and TxB2. PG-G2 and PG-H2, AA metabolites formed by COX isoforms (1 and
2), are converted to the 4 main bioactive PGs (PG-D2, PG-E2, PG-I2, PG-F2α) and thrombox-
anes (TxA2 and TxB2) [70, 71]. Most PGs have pro-inflammatory effects. For example, PG-E2
augments arterial dilation and increases microvascular permeability [71]. However, PG-E2 was
found to have an anti-inflammatory role as well by up-regulating cAMP and inducing secretion
of the anti-inflammatory IL-10 [72]. Similarly, PG-D2 attenuated inflammation in experimen-
tal models of pleuritis and colitis [71]. 6-keto-PG-F1α, the non-active hydrolysis product of
prostacyclin (PG-I2), and TxB2, the inactive degradation product of TxA2 [71], were also
decreased by t-AUCB. PG-F2α is elevated in patients with chronic inflammatory diseases [71].
In support of our findings, sEH-inhibition by AUDA-BE reversed lipopolysaccharide (LPS)-
induced increase in PG-D2, PG-E2, 6-keto-PG-F1α, and TxB2 [13]. Also, sEH-inhibition by
AUDA-BE, through increasing the concentrations of EETs, inhibited NF-κB translocation
[12]. Combination of sEH-inhibition by AUDA-BE and COX-inhibition had an additive effect
and further decreased PG-D2 and PG-E2 [12]. Therefore, the associated decrease in the mea-
sured PGs could be attributed to sEH-inhibition by t-AUCB. However, the impact of these
changes on the t-AUCB–enhanced CRH is not yet clear.
As mentioned earlier, EETs are generated from AA by cytochrome P450 (CYP) epoxygenase
enzymes, primarily CYP2C and CYP2J. We targeted the CYP epoxygenase-EET pathway using
pharmacologic inhibition of CYP-epoxygenases to further support our findings of the involve-
ment of CYP-epoxygenases in modulating CRH. sEH-inhibition increases the level of EETs by
blocking their breakdown; we investigated the effect of blocking the synthesis of EETs on CRH
using a CYP epoxygenases-inhibitor. Evidently, inhibiting CYP epoxygenases would negatively
impact EET synthesis and, therefore, their effects. P450 enzymes are highest in coronary arter-
ies and in small arterioles [2]. MS-PPOH was used as an EET-synthesis inhibitor that blocked
the role of EETs as mediators of insulin-mediated augmentation of skeletal muscle perfusion
[73]. Our data indicate that MS-PPOH significantly decreased CRH after a brief ischemia.
These findings suggest that inhibition of CYP epoxygenases by MS-PPOH decreased CRH
possibly due to inhibition of EETs synthesis. Further studies to investigate the impact of
MS-PPOH on oxylipin profiles are needed to understand the metabolic changes associated
with the inhibition of CYP epoxygenases.
This study also showed that CRH was decreased by T0070907, a PPARγ-antagonist,
whereas rosiglitazone, a PPARγ-agonist, increased CRH. Moreover, T0070907 attenuated t-
AUCB–enhanced CRH inWTmouse hearts. Studies indicated that EET effects could be medi-
ated by PPARγ receptors [20–23]. Liu et al. suggested that selective sEH inhibition potentiates
the anti-inflammatory effect in endothelial cells by increasing the retention of EETs so that
PPARγ activation is prolonged [20]. Our results suggest that PPARγ receptors are involved in
modulating CRH. Also, the attenuated t-AUCB–enhanced CRH inWT mice (by T0070907)
suggests that PPARγmay mediate CRH downstream of CYP epoxygenases-EET pathway.
In summary, the findings of this study suggest that the CYP epoxygenases-EET pathway
may have a role in mediating CRH possibly through PPARγ activation, as noted by sEH-
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inhibition, which enhanced CRH, and CYP epoxygenases-inhibition, which decreased CRH.
Also, sEH-inhibition is accompanied by changes in AA oxylipins (increased EET/DHET
ratio, decreased mid-chain HETEs, and decreased prostanoids) and LA oxylipins (increased
EpOME/DiHOME ratio, and increased HODEs), which might have collectively accounted for
the observed enhancement of CRH. Therefore, we conclude that sEH-inhibition enhances,
whereas CYP epoxygenases-inhibition attenuates CRH, PPARγ activation mediates CRH
downstream of the CYP epoxygenases-EET pathway, and the changes in oxylipin profiles asso-
ciated with sEH-inhibition collectively account for the enhanced CRH.
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